Drug intelligence / Profile preview

split-virion pandemic influenza vaccine (H5N1 strain NIBRG-14)

Development stage: Unknown
Lead developer: Sinovac Biotech
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

This is a split-virion pandemic influenza A vaccine targeting the H5N1 strain, specifically NIBRG-14. Developed by Sinovac Biotech Co., Ltd., it is designed to induce an immune response against the H5N1 influenza virus. Split-virion vaccines contain inactivated viral components, which are presented to the immune system to stimulate antibody production and cellular immunity, thereby providing protection against infection.

Beyond the preview

Go deeper on split-virion pandemic influenza vaccine (H5N1 strain NIBRG-14).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on split-virion pandemic influenza vaccine (H5N1 strain NIBRG-14).

Explore the full profile